Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

BACKGROUND: MDV3100 is a rationally-designed androgen receptor antagonist that blocks androgen receptor (AR) binding, nuclear translocation, and co-activator recruitment more effectively than the androgen receptor antagonists currently in use. MDV3100 is also unique in that it prevents DNA binding,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scher, Howard I, Beer, Tomasz M, Higano, Celestia S, Anand, Aseem, Taplin, Mary-Ellen, Efstathiou, Eleni, Rathkopf, Dana, Shelkey, Julia, Yu, Evan Y, Alumkal, Joshi, Hung, David, Hirmand, Mohammad, Seely, Lynn, Morris, Michael J, Danila, Daniel C, Humm, John, Larson, Steve, Fleisher, Martin, Sawyers, Charles L
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2948179/
https://ncbi.nlm.nih.gov/pubmed/20398925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(10)60172-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars